Wednesday, July 8, 2026

pharma · Cystic Fibrosis · Multiple Sclerosis · RARE

Ultragenyx UK

Ultragenyx UK clinical programs — 51 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Newcastle upon tyne, NE128RL, GB, NOVATO, CA HQ
2024 Founded
2 Employees
Public company Type
RARE · NYSE Ticker
Company details
Status
Public
HQ
Newcastle upon tyne, NE128RL, GB, NOVATO, CA
Founded
2024
Employees
2
Programs
201
Drugs
168
Patents
23
Intelligence · Clinical Programs

Ultragenyx UK projects

51 ClinicalTrials.gov programs sponsored by Ultragenyx UK.

Ultragenyx UK has 51 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. soy protein isolate

    Ultragenyx UK Limited

    Hereditary Hemorrhagic Telangiectasia

    phase 3 small molecule completed

    1 trial
  2. topiramate

    Ultragenyx UK Limited

    Lennox-Gastaut Syndrome

    phase 3 small molecule completed

    1 trial
  3. whole-cell pertussis vaccine

    Ultragenyx UK Limited

    Pertussis

    phase 3 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Ultragenyx UK have?

51 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.